Epizyme is exploring the potential of tazemetostat, its lead investigational agent, as a treatment for patients with difficult to treat forms of cancer in multiple clinical trials.
Clinical trials are a critical part of the drug development process designed to assess an investigational agent’s safety and effectiveness in treating a disease, adding to the industry knowledge on diseases and how they may be treated.
For information regarding access to Epizyme’s clinical trials, please visit clinicaltrials.gov. You can also email us at firstname.lastname@example.org or call us at 855-500-1011 (U.S. toll-free).
Investigator Sponsored Trials
The mission and purpose of the Investigator Sponsored Trial program are to provide support for investigator-sponsored research (“ISTs”) in disease areas that help advance the medical and scientific knowledge of Epizyme agents.
Expanded Access Program
We support expanded access to eligible investigational drugs for patients who meet specific requirements. Click here to read our early access policy.